Safety Alerts

MHRA Drug Safety Update: Botulinum toxin type A products

Published
Source
PSNC Dispensing & Supply News
Imported
15 Jul 2026

Cases of iatrogenic botulism have been reported following the therapeutic or cosmetic use of botulinum toxin containing products where the toxin’s effect extends beyond the area of treatment. Botulism caused by botulinum toxin is rare but can be life threatening. Symptoms can take up to four weeks to develop and may typically include difficulty breathing [...]

The post MHRA Drug Safety Update: Botulinum toxin type A products appeared first on Community Pharmacy England.

View original alert (opens in a new tab)

Important: This alert is gathered automatically for information only. Always refer to the original source and follow your practice’s own clinical governance procedures.

The weekly digest lists every alert published in a week, grouped by source. View the weekly digest

Back to Safety Alerts